SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
May 19 2023 - 8:30AM
SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, fully-human
immunoglobulins (hIgG), also known as fully-human polyclonal
antibodies, without the need for human donors, announced today that
it will be hosting its Virtual 2023 Annual R&D Day on
Wednesday, June 14, 2023, at 1:30 P.M. CT.
During the event, SAB will provide a company
overview of our novel immunotherapy platform DiversitAb™ along with
a portfolio progress update including recent Breakthrough Therapy
and Fast Track designations for SAB-176 anti-Influenza therapeutic
and prophylactic biologics candidate. In addition, SAB Executives
and special guest KOL speaker, Dr. Michael Haller, will present
important data validating SAB-142, a Type 1 diabetes therapeutic
candidate. Persons attending will learn about these important
advancements in a powerful new class of biologics developed by
SAB’s DiversitAb™ platform that produces targeted, high-potency,
fully-human immunoglobulin (hIgG) antibodies without the need for
human donors.
Register here to attend SAB 2023 Virtual R&D
Day: SAB 2023 Annual R&D Day Registration Link
A replay of the webcast will be made available on the SAB
website following the event.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage
biopharmaceutical company focused on the development of powerful
and proprietary immunotherapeutic polyclonal human antibodies to
treat and prevent infectious diseases and immune and autoimmune
disorders. Our development programs include infectious diseases
resulting from outbreaks and pandemics, as well as immunological,
gastroenterological, and respiratory diseases that have significant
mortality and health impacts on immune compromised patients. SAB
has applied advanced genetic engineering and antibody science to
develop Transchromosomic (Tc) Bovine™. Our versatile DiversitAb™
platform is applicable to a wide range of serious unmet needs in
human diseases. It produces natural, specifically targeted,
high-potency, fully-human polyclonal immunotherapies without the
need for human donors. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio/ and follow SAB
on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, the development and efficacy of
our influenza program, C. diff. program, type 1 diabetes program,
and other discovery programs, the results, including timing, of the
development of SAB-176, SAB-185, SAB-142 and SAB-195, including
SAB-176 Fast Track designation and Breakthrough Therapy
designation, and the outcome of potential future government and
other third-party collaborations or funded programs.
These statements are based on the current expectations of SAB
and are not predictions of actual performance, and are not intended
to serve as, and must not be relied on, by any investor as a
guarantee, prediction, definitive statement, or an assurance, of
fact or probability. These statements are only current predictions
or expectations, and are subject to known and unknown risks,
uncertainties and other factors which may be beyond our control.
Actual events and circumstances are difficult or impossible to
predict, and these risks and uncertainties may cause our or our
industry’s results, performance, or achievements to be materially
different from those anticipated by these forward-looking
statements. A further description of risks and uncertainties can be
found in the sections captioned “Risk Factors” in our most recent
annual report on Form 10-K, subsequent quarterly reports on Form
10-Q, and other filings with or submissions to, the U.S. Securities
and Exchange Commission, which are available at
https://www.sec.gov/. Except as otherwise required by law, SAB
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events,
or circumstances or otherwise.
Contact
Investor Relations:SABIR@westwicke.com
Media Relations:SABPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Apr 2024 to May 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From May 2023 to May 2024